Northeast Skate Fishery Specifications Proposed Rule (2026-2028)

NMFS has proposed new specifications for the Northeast skate fishery for fishing years 2026 through 2028. The proposed rule includes updated catch limits and an increase in per-trip possession limits for certain fisheries, aiming to align with current scientific data and provide operational flexibility.

EPA Proposed Rule: Hazardous Waste Exclusion for WRB Refining LP

The EPA is proposing to grant a hazardous waste exclusion to WRB Refining LP for up to 700 cubic yards per year of F037 petroleum refinery sludge. This proposed rule follows a petition from WRB Refining LP and, if approved, would allow the waste to be disposed of in a Subtitle D landfill instead of being managed as hazardous waste.

IRS Proposed PTIN User Fee Update and Hearing Notice

The IRS has proposed to reduce the Preparer Tax Identification Number (PTIN) user fee from $11 to $10, plus a third-party contractor fee. A public hearing has been scheduled for April 24, 2026, to discuss the proposed rulemaking.

Growth Factor Compositions for Eye Disease Treatment Patent EP4337243A1

The European Patent Office has published patent application EP4337243A1 concerning growth factor compositions for the treatment of eye diseases, filed by Claris Biotherapeutics, Inc. The patent was published on March 11, 2026.

EPO Patent EP4504780A1: Dosing for Bispecific Antibodies

The European Patent Office has published patent application EP4504780A1 concerning dosing for bispecific antibodies, specifically targeting anti-FCRH5/anti-CD3 bispecific antibodies. The patent was filed by Genentech, Inc. and lists multiple inventors.

EPHA2 Antibodies Patent EP4301785A1 Publication

The European Patent Office has published patent application EP4301785A1 concerning EPHA2 Antibodies, filed by Atreca, Inc. The publication date is March 11, 2026. This patent application relates to therapeutic antibodies and their use in treating diseases.

EPO Patent Publication: Anti-CD30 Monoclonal Antibodies and Chimeric Antigen Receptors

The European Patent Office has published patent application EP4301783A1 concerning anti-CD30 monoclonal antibodies and chimeric antigen receptors. The publication lists NantBio, Inc. as the applicant and details several inventors. This patent publication is part of the EPO Bulletin.

EPO Patent Publication EP4147696A1 - Chimeric Protein

The European Patent Office published patent application EP4147696A1 on March 11, 2026, concerning chimeric proteins. The application lists Autolus Limited as the applicant and details inventors and IPC classifications related to protein and gene technology.

Prostate Cancer Treatment: Virus, PD-1 Inhibitor, Immune Activator Combination

The European Patent Office has published patent application EP4358984A1 detailing a combination therapy for prostate cancer. This treatment involves an oncolytic virus, a PD-1 inhibitor, and an activator of the innate immune system. The patent was published on March 11, 2026.

Bacteriocin Application EP4346870A1 Published

The European Patent Office published application EP4346870A1 concerning a bacteriocin for new applications on March 11, 2026. The application was filed by Syngulon S.A. and lists Philippe Gabant and Felix Jaumaux as inventors. This publication pertains to intellectual property and potential therapeutic applications.